PRLD Stock — Prelude Therapeutics Incorporated: Cash, EV, Pipeline

Share price

$4.87

Market cap

$388.6M

Cash

$151.8M

Enterprise value

$236.8M

Balance sheet

Cash	$151.8M
Debt	$0.0M
Net cash	$151.8M
Enterprise value	$236.8M
Basic shares	98.4M shares
Fully diluted shares	104.8M shares
Fully diluted market cap	$510.2M
Cash per share	$1.54

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PRLD daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24	PRT12396	Phase 1	Polycythemia Vera (PV); Myelofibrosis (MF); Myeloproliferative Neoplasms (MPNs)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PRT12396

Phase 1 · Active Modality: small molecule inhibitor

Target JAK2 (V617F)

Indications

polycythemia vera (PV) (Phase 1)
myelofibrosis (MF) (Phase 1)

Catalysts

— H2 2026

Status note Lead candidate; mutant-selective JAK2V617F inhibitor. IND cleared Feb 2026; enrolling open-label multicenter Phase 1 safety/efficacy study in PV and MF patients.

PRT13722

Preclinical · Active

Target KAT6A

Indications

HR+ breast cancer (Stage not disclosed)

Catalysts

— Q4 2026
— mid-2026

Status note Lead development candidate; preclinical data presented at AACR 2026. Pending IND clearance, Phase 1 in HR+ breast cancer expected to initiate Q4 2026. Modality/target not stated in excerpts.

SMARCA2/4 dual degrader programs

Preclinical · Active Modality: degrader (ADC-conjugated payload)

Target SMARCA2/4

Status note Described as a novel, potent SMARCA2/4 dual degrader as a degrader payload conjugated to multiple antibodies; preclinical PoC disclosed Oct 2024. Filing states the company has paused or discontinued these programs (expense reclassification); filing does not specify which.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PRT12396
Lead indication	Polycythemia Vera (PV)
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07469891	Phase 1	Recruiting	Sponsor	PRLD	—	Polycythemia Vera (PV); Myelofibrosis (MF); Myeloproliferative Neoplasms (MPNs)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Prelude Therapeutics Incorporated on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	19,404,757	+2,284,602	1.96%	2026-08-14
Baker Bros. Advisors	10,123,824	no change	0.27%	2026-08-14
Sphera Biotech	1,019,832	+461,493	0.78%	2026-08-14
ADAR1 Capital Management	900,900	+748,075	0.23%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PRLD — Prelude Therapeutics Incorporated